Nihon University

Gentier Biosystems Incorporation

Gentier Biosystems, Inc.

Noboru Fukuda

Hiroshi Sugiyama

Satoshi Saito

Takahiro Ueno

Daisuke Kawabe

Hirofumi Kishioka

Shinichiro Yokoyama

A TGF-&#x3b2; gene expression inhibitor containing a pyrrole-immidazole polyamide comprising an N-methylpyrrole unit (hereinafter also referred to as Py), an N-methylimidazole unit (hereinafter also referred to as Im) and a &#x3b3;-aminobutyric acid unit which can be folded into an U-shaped conformation at the above-described &#x3b3;-aminobutyric acid unit site in a minor groove of a double-stranded region (hereinafter referred to as the target region) containing a part or the whole of the following base sequence (SEQ ID NO: 2) corresponding to &#x2212;450 to &#x2212;310 of human transforming growth factor &#x3b2;1 (hereinafter also referred to as h TGF-&#x3b2;1) promoter and a strand complementary thereto and in which a Py/Im pair, an Im/Py pair and a PY/Py pair correspond respectively to a C-G base pair, a G-C base pair and an A-T base pair and a T-A base pair.

TGF-&#x3b2; gene expression inhibitor

A TGF-&#x3b2; gene expression inhibitor containing a pyrrole-imidazole polyamide having N-methylimidazole unit (hereinafter also referred to as Py), N-methylimidazole unit (hereinafter also referred to as Im) and &#x3b3;-aminobutyrate unit which can be holded into an U-shaped conformation at the &#x3b3;-aminobutyrate unit in the minor groove in a double helix region (hereinafter referred to as the target region) containing a complementary chain corresponding to the sequence at the &#x2212;557 to &#x2212;536 in the base sequence of a human transforming growth factor &#x3b2;1 (hereinafter also referred to as hTGF-&#x3b2;1) promoter, either as a whole or a part thereof: TAAAGGAGAGCAATTCT-TACAG (SEQ ID NO: 1) wherein a Py/Im pair corresponds to a C-G base pair, an Im/Py pair corresponds to a G-C base pair, and Py/Py pairs correspond respectively to an A-A base pair and a T-A base pair.

To provide infusion therapy that can effectively transluminally deliver drugs or the like to a target spot without invading areas other than a diseased area. The infusion therapy is for administering a drug, cells or the like, or inserting a treatment instrument into the target diseased area. A blood vessel area including a bifurcated blood vessel connecting to the diseased area is occluded at the distal and the proximal region thereof to form an occluded area, and the drugs or the like are pumped and supplied to the occluded area, which causes the drugs or the like to flow retrogressively and retentively in the bifurcated blood vessel connecting in the occluded area, and be infused and administered to the diseased area.

Infusion therapy

A ribozyme comprising the following nucleotide sequence (SEQ ID NO:14) (I): wherein A, C, G and U represent a ribonucleotide whose base component is adenine, cytosine, guanine and uracil, respectively, Nand Nare at least one pair of nucleotides capable of forming a complementary base pair with each other, and Nis at least three nucleotides capable of forming a loop.

Growing community of inventors

Tokyo, Japan

Noboru Fukuda